MAP conference agenda, Temple University, Philadelphia March 2017

Friday, March 24th

0800-0815 Welcome remarks- Kuenstner, Behr, Rothstein and Chamberlin

The goals of the meeting include:

1) review available MAP diagnostic methods including culture, molecular diagnostic and serologic methods
2) review antibiotic therapies used to date in human trials and human case reports
3) review evidence of role of MAP in human disease(s)
4) building on conclusions of the American Academy of Microbiology stating that MAP is associated with Crohn’s disease and implicating but not proving that MAP causes disease in humans. An additional goal is to communicate recent advances linking MAP to human chronic inflammatory syndromes.
5) Summarize concern that MAP is a zoonosis

Following the conclusion of the meeting, we aim to write a consensus document that is submitted for publication in a peer review open access medical journal. The document will describe the design of a rigorous controlled clinical trial of antibiotic therapy in Crohn’s disease (CD).

The questions to address during the conference include: 1) Should the trial take all-comers or only people with MAP associated disease? 2) If the latter, which assay(s) would we recommend as inclusion criteria? 3) If agreement can be reached on which assay(s) can be used to separate patients with MAP-associated disease from patients without MAP-associated disease, which combination(s) of antibiotics would we study in a controlled clinical trial? 4) What is the nature of the control arm? 5) Should the group design a separate study to compare different MAP diagnostic methods, as a prerequisite for an interventional study?

It is anticipated that a consensus document would be helpful in procuring funding from the NIH and foundations for the studies and clinical trials recommended in the document.

0815-0845 Collins, MAP: A Zoonotic Pathogen

Session 1- What is desirable in a MAP diagnostic test?

0845-0905 Vivek Kapur, what are the accepted tests for diagnosis of MAP infection and disease in livestock?

0915-0935 Marcel Behr, what have we learned from evaluation of molecular tests in experimental models of infection?
0945-1005 Jerry Mazurek, how was the Quantiferon test for latent TB infection validated in the absence of a gold standard?

1015-1035 Adrienne McNees, what have we seen when culturing tissue and blood for MAP?

1045-1100 break

Section 2- MAP detection in humans

1100-1120 Shoor Vir Singh, MAP stool culture and case report Frontiers in Medicine 2016

1130-1150 John Aitken, MAP blood culture and diagnostic testing

1200-1220 Horacio Bach, serologic ELISA MAP diagnostic tests

1230-1250 Tim Bull, the dark art of MAP culture

1300-1400 catered lunch at the MERB first floor conference room

Section 3- Overview of efforts identifying ‘MAP associated Crohn’s disease’ and treatment

1400-1420 William Chamberlin, case report and summary of antibiotic trials in CD from Expert Rev Clin Immunol 2011 and open label trials of antibiotics in CD

1430-1450 Todd Kuenstner, case reports from WJG 2015 article

1500-1520 Nicole Parrish, case report from Case Rep Gastroenterol 2015 and potential role of metronidazole

1530-1550 Harry Oken case report currently under journal review

1600-1615 break

Section 4- MAP in the biosphere

1615-1635 Ellen Pierce, human infection with MAP, the Forest, Virginia IBD outbreak

1645-1705 David Graham, MAP prevalence study from Bahrain

1715- 1735 Irene Grant, detection of MAP in dairy products and novel MAP detection methods with application to blood testing

1745 adjournment
Saturday, March 25th

Session 5- What is the best way to treat MAP infection in humans?
0800-0820 Tom Borody, open label clinical trials of antibiotics in CD
0830-0850 Ira Shafran, open label clinical trials of antibiotics in CD
0900-0920 Patrick McLean or Ira Kalfus overview of RedHill Biopharma study
0930-0950 Robert Greenstein, Unacknowledged growth inhibition of MAP by immunomodulators critically flaws all prior antibiotic studies in IBD
1000-1015 break

Session 6- MAP infection in mammals and the host response
1015-1035 William Chamberlin, evidence that CD is a disease of innate immune deficiency
1045-1105 Bill Davis, immunology of MAP infection in cattle with implications for human infection
1115-1135 Leonardo Sechi, MAP, type I diabetes mellitus and multiple sclerosis, what is the connection?
1145-1205 Gilles Monif, the pathogenesis of Crohn’s disease and its therapeutic ramifications
1215-1315 catered lunch at the MERB first floor conference room

Session 7- What are the diagnostic and therapeutic ingredients for a successful trial?
1315-1400 Discussion on diagnostic methods to embed within a trial and the design of a comparative study of these methods
1400-1500 Discussion of the best anti-MAP antibiotic combinations for the recommended trial

Section 8- Conclusion
1500-1545 Discussion of what a treatment study can and cannot answer regarding MAP and human disease
1545-1645 Discussion of whether MAP causes human disease. It is not expected that there will be a consensus at this time within the group on this issue, but the discussion could have an impact on the public health aspect of MAP in the food supply.
1645-1715 Closing remarks Kuenstner, Behr, Rothstein and Chamberlin

The closing remarks will summarize:
1) What did we learn about the available MAP diagnostic methods?
2) What do we know about antibiotics used in human clinical trials and in case reports?
3) What are the next steps and who should take the next steps?

1715 adjournment

CONFERENCE LOCATION AND LODGING INFORMATION

The conference will be held at the Lewis Katz School of Medicine Medical Education and Research Building (MERB) in the first floor conference room 105. The address is: 3500 North Broad Street, Philadelphia, Pa. The recommended mode of transportation from the hotel to the conference is an Uber ride. Alternatively, the Broad Street subway line may be used. The MERB is between the Allegheny and Erie subway stops, but the Erie stop is closer to the conference location. Paid parking is available at a Temple University garage on the corner of West Ontario Street and Germantown Ave. The GPS address is 1303 West Ontario Street and the entrance is on West Ontario Street. As you enter the garage, take a ticket from the machine. Payment of $12.00 for the day is made when you exit the garage. This garage is a short walk up Broad Street to the MERB.

When you arrive at the MERB on Broad Street, you must sign in at the front desk on the ground floor after identifying yourself as a MAP conference attendee.

Please note that there is no registration fee for the conference. However, the attendees are responsible for the payment of transportation, hotel and meal fees. There will be a charge for the catered luncheons during the conference.

The recommended hotel for those attendees requiring lodging is the DoubleTree by Hilton, Philadelphia Center City 237 S. Broad Street, Philadelphia PA 19107. Attendees are eligible for the Temple University corporate rate of $168.00 for one or two occupants per night. Please note that these rooms are subject to availability and thus you are encouraged to make reservations as soon as possible. In order to make the reservations, please use the following link.


This website works best with Internet Explorer or Firefox web browsers. You may experience difficulties using Google Chrome.

All attendees and presenters will be asked to disclose any financial conflicts of interest prior to their presentation and prior to submission of a document for publication.